KORTUC INC.

The Wilson Sonsini report reveals a striking statistic: 39% of companies raised funds at flat or down valuations in Q3 2024. ???This is an unexpectedly high ratio, reflecting the challenging market conditions startups are navigating today.?? This trend brought to mind an insightful panel discussion at TechCrunch 2024 titled "How to Raise in 2025 if You Have Taken a Flat, Down, or Extension Round." ??During the session, Elliott Robinson shared a powerful perspective: despite market challenges, the companies that stick it out and adapt can come out as winners.???? This is an encouraging reminder for all startups currently raising funds. The road may be tough, but staying strong and making smart choices can lead to long-term success.?? #Startups #Funding #WilsonSonsini #TechCrunch2024 #Entrepreneurship #KORTUC

It's been a year since we became members of Japan Innovation Campus! ?? With the incredible support from Japan Innovation Campus and JETRO, we have accomplished so much: 1. We introduced KORTUC's technology to numrous guests visiting the campus, sharing our mission and impact ?? . 2. We expanded our network significantly, receiving valuable advice and mentorship that continues to guide our journey ? .Gail Christine Gannon Laurent Rains Anne-Sophie Reinckens JC Muyl 3. We hosted influential visitors, including potential strategic partners and prospective investors, in our beautiful office space??. We’re continuing to work hard to deliver our product as soon as possible. We will also increase awareness of KORTUC’s technology among people who will benefit from this advancement. Thank you to everyone who has supported us on this journey! #Innovation #Healthcare #KORTUC #JETRO #JapanInnovationCampus #Biotech #Radiotherapy #Radiosensitizer

This recent study demonstrates KORTUC's effectiveness in improving the quality of life for cancer patients ? ?

?? KORTUC Phase 2 Clinical Trial Milestone: Achieved 110 Enrollments!!! ?? We’re proud to share that we have reached a major milestone of 110 patients enrolled in our ongoing Phase 2 clinical trial for breast cancer. This study focuses on the efficacy and safety of KORTUC’s innovative hydrogen peroxide-based technology, designed to enhance radiation therapy by overcoming tumor hypoxia—a critical challenge in cancer treatment. Led by our esteemed investigator, Dr. Navita Somaiah at the Institute of Cancer Research, this trial spans 11 leading institutes across the UK and India, with teams dedicated to bringing new hope to patients worldwide. This enrollment milestone marks a crucial step in making our treatment a global reality! A heartfelt thank you to our clinical partners and every patient participating in the study. Stay tuned for more exciting updates! #KORTUC #BreastCancerResearch #ClinicalTrial #CancerCare #Radiotherapy #Radiosensitizer

??TechCrunch 2024?? Vinod Khosla, founder of Khosla Ventures, shared his exciting vision for the future . With his strong optimism ?? about AI, he described a world where human labor could cost almost nothing, boosting productivity like never before and allowing people to focus on what truly matters ??. Khosla also highlighted that the biggest changes and innovations don’t come from big companies, but from determined entrepreneurs ??. The key, he said, is finding a real problem and sticking with it—because persistence is the heart of true entrepreneurship. This really connects with our mission at KORTUC INC. We’re tackling a big challenge in cancer treatment: helping tumors respond better to radiotherapy. Starting from Dr. Ogawa’s research in 2006, we’ve come a long way, and now we’re in the final stage of clinical trials ??. It’s been a long journey, but we can’t wait to see the positive impact KORTUC will bring to patients soon ??. #TechCrunch2024 #Innovation #AI #KORTUC #CancerCare #CancerTreatment #RadiationTherapy #Entrepreneurship

?? We are thrilled to share that Kazuyuki Matsuda, our CEO, was one of the panelists at the recent event hosted by Japan Society of Northern California. The panel focused on the challenges of crossing borders, with insightful discussions on navigating the transition from Japan to the US and entering the Japanese market from the US. It was an inspiring conversation, filled with experiences that highlight the complexities and opportunities of international business. We’re proud of Kazu for contributing to this important dialogue! #JapanSocietyofNorthernCalifornia#CrossBorderChallenges #GlobalLeadership #JapanUSRelations #Innovation#KORTUC

?? Exciting Research with KORTUC from a Nature Portfolio Journal ?? A new study, led by Dr. Navita Somaiah, the lead investigator of the Phase 2 clinical trial for breast cancer at The Institute of Cancer Research (ICR), and Dr. Samantha Nimalasena, was recently published in BJC Reports, a journal in the prestigious Nature Portfolio ??. The study reports that KORTUC reoxygenates hypoxic tumors, a key factor in overcoming radiation resistance, showing its potential to revolutionize the treatment of hypoxic tumors across various cancer types . ?? The study also highlights KORTUC’s role as an innovative intratumoural injection containing hydrogen peroxide, aimed at improving cancer treatment outcomes. ? Check out the full study on the Nature website for more in-depth findings! https://lnkd.in/gNgkDFDe #CancerResearch #Oncology #KORTUC #Radiotherapy #TumorReoxygenation #ICR #ClinicalTrials #NaturePortfolio #BJCReports #Radiosensitizer #BreastCancer

??How Hypoxia (Low oxygen in tumors) Affects Cancer Treatment ?? A study by the Oslo University group reveals a significant gap in treatment outcomes between normal and hypoxic tumors (Fjeldbo et al 2020). While radiotherapy leads to an over 80% 5-year Progression-Free Survival rate for normal tumors, hypoxic tumors show a drastically lower rate—less than 30% in cervical cancer. ?? At KORTUC, we are tackling this challenge by eliminating hypoxia in tumors, giving patients a better chance at survival. ?? By addressing this critical issue, we’re committed to improving outcomes for those who need it most! ?? #CancerResearch #CancerTreatment #Hypoxia #Radiotherapy #InnovationInHealthcare #KORTUC #PatientCare #HealthcareInnovation#OsloUniversity

?? KORTUC: Enhancing Not Just Radiotherapy, but Immunotherapy Too! ?? At KORTUC, we’ve always been focused on advancing cancer treatment through our breakthrough radiosensitizer, KRC-01. While KRC-01 is well-known for its ability to enhance radiotherapy by addressing tumor hypoxia, our research shows it also plays a crucial role in boosting the body’s immune response against cancer. ??? Professor Yosuke Togashi presented groundbreaking research on KRC-01’s impact at AACR, and this study has since been published in Cancer Science. The research highlights how KRC-01 overcomes tumor hypoxia, enhancing radiotherapy while also supporting the immune system’s ability to fight tumors. This discovery opens the door for combining KRC-01 with immunotherapy, offering a powerful dual-action approach to cancer treatment.?? With over half of U.S. and European cancer patients undergoing radiotherapy, the potential of KRC-01 is clear — not only to improve radiotherapy but also to unlock new possibilities in immunotherapy ? #KORTUC #Immunotherapy #CancerTreatment #OncologyInnovation #Radiosensitizer #Hypoxia #CancerResearch

?? The mechanism of our drug: Hydrogen Peroxide (H?O?) as the Key Component ?? To make hypoxic (low oxygen) tumors sensitive to radiation, we inject KRC-01 directly into the tumor just before radiotherapy. Hydrogen peroxide is broken down into oxygen and water, supplying oxygen, eliminating hypoxia, and transforming radioresistant tumor cells into radiosensitive ones. ? To deliver the KRC-01 solution, we have developed a drug in a prefilled syringe format, backed by robust IP. The active pharmaceutical ingredient is hydrogen peroxide, with sodium hyaluronate as a functional excipient. Based on our experience and track record with patients, our syringe format allows for easy, safe, and effective injection into tumors.